Innate Pharma S.A.
IPH.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €4,860 | €7,776 | €12,345 | €21,443 |
| % Growth | -37.5% | -37% | -42.4% | – |
| Cost of Goods Sold | €20,520 | €22,904 | €29,076 | €24,569 |
| Gross Profit | -€15,660 | -€15,128 | -€16,731 | -€3,126 |
| % Margin | -322.2% | -194.5% | -135.5% | -14.6% |
| R&D Expenses | €20,520 | €22,906 | €28,433 | €23,722 |
| G&A Expenses | €9,611 | €10,607 | €9,418 | €8,970 |
| SG&A Expenses | €9,767 | €9,286 | €9,582 | €8,543 |
| Sales & Mktg Exp. | €156 | €473 | €164 | €174 |
| Other Operating Expenses | -€20,520 | €0 | -€28,433 | -€23,120 |
| Operating Expenses | €9,767 | €32,192 | €9,582 | €9,145 |
| Operating Income | -€25,427 | -€25,262 | -€26,313 | -€12,270 |
| % Margin | -523.2% | -324.9% | -213.1% | -57.2% |
| Other Income/Exp. Net | €4,083 | €555 | €1,549 | €2,983 |
| Pre-Tax Income | -€21,344 | -€24,707 | -€24,764 | -€9,288 |
| Tax Expense | €0 | -€3,438 | €0 | €0 |
| Net Income | -€21,344 | -€24,707 | -€24,764 | -€9,288 |
| % Margin | -439.2% | -317.7% | -200.6% | -43.3% |
| EPS | -0.25 | -0.3 | -0.31 | -0.12 |
| % Growth | 16.7% | 3.2% | -158.3% | – |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.11 |
| Weighted Avg Shares Out | 85,376 | 60,926 | 60,926 | 60,926 |
| Weighted Avg Shares Out Dil | 86,937 | 81,246 | 80,872 | 80,587 |
| Supplemental Information | – | – | – | – |
| Interest Income | €793 | €4,810 | €2,538 | €11,938 |
| Interest Expense | €229 | €3,675 | €600 | €3,022 |
| Depreciation & Amortization | €366 | €848 | €750 | €1,874 |
| EBITDA | -€25,061 | -€23,053 | -€25,563 | -€10,396 |
| % Margin | -515.7% | -296.5% | -207.1% | -48.5% |